Shobith Rangappa
YOU?
Author Swipe
View article: Repurposing risperidone as an anti-angiogenic agent for triple-negative breast cancer: a computational to in ovo investigation
Repurposing risperidone as an anti-angiogenic agent for triple-negative breast cancer: a computational to in ovo investigation Open
Introduction Triple-negative breast cancer (TNBC) is a challenging subtype of breast cancer to treat because it lacks the expression of progesterone receptor (PR), estrogen receptor (ER), and human epidermal growth factor receptor 2 (HER2)…
View article: Multi-functional Ag2O-NiO composite bio-catalyst: Efficacy in breast cancer and anti-microbial properties
Multi-functional Ag2O-NiO composite bio-catalyst: Efficacy in breast cancer and anti-microbial properties Open
Silver and nickel composites are known for enhancing biocatalytic activity and have substantial potential in biomedical engineering due to their comprehensive applications. Here, we synthesized an Ag2O/NiO composite using the microwave hyd…
View article: 1,2,3‐Triazole Tethered Spiro[Indoline‐Oxirane] Derivatives Induce Anticancer Effects in Human Hepatoma Cells
1,2,3‐Triazole Tethered Spiro[Indoline‐Oxirane] Derivatives Induce Anticancer Effects in Human Hepatoma Cells Open
Epoxides are well‐known compounds as anticancer agents. In this article, we present the synthesis of novel 3′‐phenyl‐1‐((1‐aryl‐1 H ‐1,2,3‐triazol‐5‐yl)methyl)spiro[indoline‐3,2′‐oxiran]‐2‐one derivatives by the regioselective reaction of …
View article: Assessing the Efficacy and Biological Benefits of Withanolide-rich Withania somnifera Root Extract
Assessing the Efficacy and Biological Benefits of Withanolide-rich Withania somnifera Root Extract Open
The medicinal plant Withania somnifera, usually referred to as Ashwagandha, is a member of the Solanaceae family. The presence of Withanolides in the roots is responsible for a number of pharmacological effects in Ashwagandha. Withanolides…
View article: Antimicrobial Activity of Novel Piperazine Molecules
Antimicrobial Activity of Novel Piperazine Molecules Open
A series of twenty two novel piperazine derivatives were screened for their antimicrobial activities by disc diffusion method and micro dilution method against the ATCC strains of certain selected Gram- positive (MRSA, Staphylococcus aureu…
View article: Enhanced Bioavailability and Efficacy of Bacopa Extract and Ebelin Lactone: Preparation and Biological Evaluation
Enhanced Bioavailability and Efficacy of Bacopa Extract and Ebelin Lactone: Preparation and Biological Evaluation Open
Although Bacopa monnieri extract is well known for its cognitive and memory support, it has received minimal attention in pharmacy due to its terrible palatability and poor bioavailability. This study aimed to develop an improved, cost-eff…
View article: Alternative Approach to Access 5-Hydroxy-1H-pyrrol-2-(5H)-ones from Base-Induced Tandem Intramolecular Cyclization of Sulfur Ylide with Ketones and 1,3-Hydroxy Rearrangement
Alternative Approach to Access 5-Hydroxy-1H-pyrrol-2-(5H)-ones from Base-Induced Tandem Intramolecular Cyclization of Sulfur Ylide with Ketones and 1,3-Hydroxy Rearrangement Open
An easily adaptable protocol for the preparation of 5-hydroxy-1H-pyrrol-2(5H)-ones from readily available starting materials has been reported. The reaction of sulfur ylides with carbonyl compounds is a common approach to synthesizing epox…
View article: CCDC 2267726: Experimental Crystal Structure Determination
CCDC 2267726: Experimental Crystal Structure Determination Open
An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available …
View article: Design, synthesis and docking studies of novel 4-aminophenol-1,2,4-oxadiazole hybrids as apoptosis inducers against triple negative breast cancer cells targeting MAP kinase
Design, synthesis and docking studies of novel 4-aminophenol-1,2,4-oxadiazole hybrids as apoptosis inducers against triple negative breast cancer cells targeting MAP kinase Open
In our study, a series of novel 4-aminophenol benzamide-1,2,4-oxadiazole hybrid analogues have been designed and synthesized by condensing 4-hydroxyphenyl arylamides (3a–c) and 5-chloromethyl-3-aryl-1,2,4-oxadiazoles (6a–d). The structure …
View article: Supplementary Figure S3 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Supplementary Figure S3 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer Open
Supplementary Figure S3 shows PhosphoKinase array analysis in MiaPaCa2 cells treated with Uro A.
View article: Supplementary Materials and Methods from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Supplementary Materials and Methods from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer Open
Supplementary Materials and Methods
View article: Supplementary Figure S1 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Supplementary Figure S1 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer Open
Supplementary Figure S1 shows Uro B and Uro C treatment on PDAC cell viability.
View article: Supplementary Figure S2 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Supplementary Figure S2 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer Open
Supplementary Figure S2 shows cell apoptosis and cell cycle analysis after Uro A treatment in PDAC cells.
View article: Supplementary Figure S5 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Supplementary Figure S5 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer Open
Supplementary Figure S5 shows densitometry analyses of pAKT and pP70S6K in HPNE and HPNE-KRAS cells.
View article: Data from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Data from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer Open
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy and is highly resistant to standard treatment regimens. Targeted therapies against KRAS, a mutation present in an overwhelming majority of PDAC cases, have been largely in…
View article: Supplementary Figure S6 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Supplementary Figure S6 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer Open
Supplementary Figure S6 shows body weight of PKT mice and xenograft mice.
View article: Supplementary Materials and Methods from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Supplementary Materials and Methods from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer Open
Supplementary Materials and Methods
View article: Supplementary Figure S2 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Supplementary Figure S2 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer Open
Supplementary Figure S2 shows cell apoptosis and cell cycle analysis after Uro A treatment in PDAC cells.
View article: Supplementary Tables S1-S3 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Supplementary Tables S1-S3 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer Open
Supplementary Tables shows primary antibodies used for Western blot, IHC, Flow Cytometry and IC50 values for Uro A.
View article: Supplementary Figure S5 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Supplementary Figure S5 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer Open
Supplementary Figure S5 shows densitometry analyses of pAKT and pP70S6K in HPNE and HPNE-KRAS cells.
View article: Supplementary Figure S4 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Supplementary Figure S4 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer Open
Supplementary Figure S4 shows AKT knockdown analysis, K8484 cells analyzed for PDK1, pGSK3β and p4E-BP1 levels with Uro A treatment, and AKT activator SC79 with Uro A treatment on cell proliferation.
View article: Supplementary Figure S4 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Supplementary Figure S4 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer Open
Supplementary Figure S4 shows AKT knockdown analysis, K8484 cells analyzed for PDK1, pGSK3β and p4E-BP1 levels with Uro A treatment, and AKT activator SC79 with Uro A treatment on cell proliferation.
View article: Supplementary Figure S1 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Supplementary Figure S1 from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer Open
Supplementary Figure S1 shows Uro B and Uro C treatment on PDAC cell viability.
View article: Data from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer
Data from Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer Open
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy and is highly resistant to standard treatment regimens. Targeted therapies against KRAS, a mutation present in an overwhelming majority of PDAC cases, have been largely in…